期刊
MOVEMENT DISORDERS
卷 31, 期 2, 页码 214-224出版社
WILEY
DOI: 10.1002/mds.26377
关键词
vaccination; -synuclein; Parkinson's disease; MSA; synucleinopathies
资金
- Michael J Fox Foundation
- European Union [602999]
Vaccination is increasingly being investigated as a potential treatment for synucleinopathies, a group of neurodegenerative diseases including Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies associated with -synuclein pathology. All lack a causal therapy. Development of novel, disease-altering treatment strategies is urgently needed. Vaccination has positioned itself as a prime strategy for addressing these diseases because it is broadly applicable, requires infrequent administration, and maintains low production costs for treating a large population or as a preventive measure. Current evidence points to a causal role of misfolded -synuclein in the development and progression of synucleinopathies. In the past decade, significant progress in active immunization against -synuclein has been shown both in preclinical animal models and in early clinical development. In this review, we describe the state-of-the-art in active immunization approaches to synucleinopathies, with a focus on advances in Parkinson's disease (PD) and multiple-system atrophy (MSA). We first review preclinical animal models, highlighting their progress in translation to the clinical setting. We then discuss current clinical applications, stressing different approaches taken to address -synuclein pathology. Finally, we address challenges, trends, and future perspectives of current vaccination programs. (c) 2015 International Parkinson and Movement Disorder Society
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据